Gregory Colby

Gregory Colby has a diverse work experience in the field of research and biology. Gregory started their career as an Undergraduate Researcher at the University of Massachusetts Amherst in 2008. Gregory then moved on to work as a Graduate Student at Vanderbilt University, where they managed laboratory functions and conducted various experiments related to insect genetics and population analysis.

Gregory later worked as an Adjunct Professor at Belmont University before joining Harvard Medical School as a Research Associate. At Harvard, they played a crucial role in building the Human Proteome Interaction Network and also developed a high-throughput pipeline through molecular biology experiments and cell culture.

Gregory then worked at QIAGEN as a Senior Research Associate, where they conducted molecular biology and sequencing experiments for the development of the Qiagen next-generation sequencing platform. Gregory also managed configuration tracking for the NGS sequencing subsystem.

After QIAGEN, Gregory worked as a Research Associate at Neon Therapeutics, where they specialized in cell culture. Gregory then joined The RNA Medicines Company and Fulcrum Therapeutics as a Research Associate II, focusing on molecular biology and research tasks.

Most recently, Gregory worked at Casma Therapeutics as a Senior Associate Scientist, contributing to various scientific projects until March 2023.

As of March 2023, Gregory is employed at Mediar Therapeutics as a Scientist I.

Gregory Colby completed their education from 2004 to 2009 at the University of Massachusetts Amherst, where they earned a Bachelor of Science (B.S.) degree in Environmental Science. Gregory then pursued further studies from 2009 to 2012 at Vanderbilt University, graduating with a Master of Science (M.S.) degree in Biology, General.